Pacira Pharmaceuticals has announced results from a study evaluating the use of Exparel (bupivacaine liposome injectable suspension) in the transversus abdominis plane (iTAP) for postsurgical pain management. Exparel iTAP was found to reduce the amount of and need for opioids following surgery for pain control.
A recent independent study of patients undergoing laparoscopic bariatric surgery, led by Andras Sandow, MD, FACS, FASMBS of the Hallmark Health Center for Weight Management/Weight Loss Surgery in Medford, MA, examined the use of Exparel iTAP for postsurgical pain control.
A total of 90 patients were recruited, half of whom were given multimodal therapy including an Exparel iTAP and half (control group) received ketorolac and lidocaine with bupivacaine/epinephrine for perioperative pain, and hydromorphone pain-controlled analgesia (PCA) pumps for postsurgical pain. If flatus occurred, both groups were allowed oral opioids on the second day after surgery. Patient receiving Exparel iTAP had a 60.7% reduction in opioid consumption at 48 hours post-surgery (P<0.001) and a higher return of bowel function within 48 hours (P<0.001).
A Phase 4 TRANSCEND trial also studied the use of Exparel iTAP in patients undergoing gynecological or colorectal surgeries. Those receiving the Exparel iTAP showed improved Day 3 Overall Benefit of Analgesia Scores (OBAS) compared to those receiving a normal saline iTAP (P<0.05). These results echo previous findings from two studies which showed a high level of patient satisfaction and low pain scores after open abdominal hernia repair and robotic laparoscopic prostatectomy from patients receiving Exparel iTAP.
Exparel is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.
For more information call (855) 793-9727 or visit Exparel.com.